Literature DB >> 23041672

Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation.

Yanqing Gong1, Dan Wang, Javid A Dar, Prabhpreet Singh, Lara Graham, Weijun Liu, Junkui Ai, Zhongcheng Xin, Yinglu Guo, Zhou Wang.   

Abstract

Androgen receptor (AR) plays a key role in prostate development and carcinogenesis. Increased expression and/or stability of AR is associated with sensitization of prostate cancer cells to low levels of androgens, leading to castration resistance. Hence, understanding the mechanisms regulating AR protein stability is clinically relevant and may lead to new approaches to prevent and/or treat prostate cancer. Using fluorescence microscopy, Western blot, and pulse chase assay, we showed that nuclear export signal (NES)(AR), a nuclear export signal in the ligand binding domain (LBD) of AR, can significantly enhance the degradation of fusion protein constructs in PC3 prostate cancer cells. The half-life of GFP-NES(AR) was less than 3 h, which was 10 times shorter than that of green fluorescent protein (GFP) control. Further analysis showed that NES(AR) can signal for polyubiquitination and that degradation of NES(AR)-containing fusion proteins can be blocked by proteasome inhibitor MG132. Ubiquitination of GFP-AR or GFP-LBD was suppressed in the presence of dihydrotestosterone, which is known to suppress NES(AR) while inducing nuclear localization signal 2 in AR or LBD, suggesting that the export activity of NES(AR) is required for NES(AR)-mediated polyubiquitination. Treatment with MG132 also induced aggresome formation of NES(AR)-containing fusion proteins in perinuclear regions of the transfected PC3 cells, indicating a role for NES(AR) in inducing unfolded protein responses. The above observations suggest that NES(AR) plays a key role in AR ubiquitination and proteasome-dependent degradation in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041672      PMCID: PMC3512072          DOI: 10.1210/en.2012-1841

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  46 in total

1.  Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.

Authors:  A Rodriguez-Gonzalez; K Cyrus; M Salcius; K Kim; C M Crews; R J Deshaies; K M Sakamoto
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

Review 2.  Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

Authors:  Masaki Shiota; Akira Yokomizo; Seiji Naito
Journal:  J Mol Endocrinol       Date:  2011-07-12       Impact factor: 5.098

3.  Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor.

Authors:  V Georget; J M Lobaccaro; B Terouanne; P Mangeat; J C Nicolas; C Sultan
Journal:  Mol Cell Endocrinol       Date:  1997-04-25       Impact factor: 4.102

4.  Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.

Authors:  Zhigang Kang; Asta Pirskanen; Olli A Jänne; Jorma J Palvimo
Journal:  J Biol Chem       Date:  2002-10-09       Impact factor: 5.157

Review 5.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

6.  Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor.

Authors:  Anthony J Saporita; Qiuheng Zhang; Neema Navai; Zehra Dincer; Junghyun Hahn; Xiaoyan Cai; Zhou Wang
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  The RING finger protein SNURF modulates nuclear trafficking of the androgen receptor.

Authors:  H Poukka; U Karvonen; N Yoshikawa; H Tanaka; J J Palvimo; O A Jänne
Journal:  J Cell Sci       Date:  2000-09       Impact factor: 5.285

9.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

Review 10.  The ubiquitin system, disease, and drug discovery.

Authors:  Matthew D Petroski
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

View more
  13 in total

1.  Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2.

Authors:  Yoshinori Matsumoto; Jose La Rose; Oliver A Kent; Melany J Wagner; Masahiro Narimatsu; Aaron D Levy; Mitchell H Omar; Jiefei Tong; Jonathan R Krieger; Emily Riggs; Yaryna Storozhuk; Julia Pasquale; Manuela Ventura; Behzad Yeganeh; Martin Post; Michael F Moran; Marc D Grynpas; Jeffrey L Wrana; Giulio Superti-Furga; Anthony J Koleske; Ann Marie Pendergast; Robert Rottapel
Journal:  J Clin Invest       Date:  2016-10-31       Impact factor: 14.808

Review 2.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

3.  Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Authors:  Qiang Wu; Manish Kohli; H Robert Bergen; John C Cheville; R Jeffrey Karnes; Hong Cao; Charles Y F Young; Donald J Tindall; Mark A McNiven; Krishna Vanaja Donkena
Journal:  Mol Cancer Ther       Date:  2014-03-27       Impact factor: 6.261

4.  Splicing Factor Prp8 Interacts With NES(AR) and Regulates Androgen Receptor in Prostate Cancer Cells.

Authors:  Dan Wang; Minh M Nguyen; Khalid Z Masoodi; Prabhpreet Singh; Yifeng Jing; Katherine O'Malley; Javid A Dar; Rajiv Dhir; Zhou Wang
Journal:  Mol Endocrinol       Date:  2015-09-15

Review 5.  The link between androgen receptor splice variants and castration-resistant prostate cancer.

Authors:  Cynthia C T Sprenger; Stephen R Plymate
Journal:  Horm Cancer       Date:  2014-05-06       Impact factor: 3.869

6.  Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.

Authors:  Shidong Lv; Qiong Song; Guang Chen; Erdong Cheng; Wei Chen; Ryan Cole; Zeyu Wu; Laura E Pascal; Ke Wang; Peter Wipf; Joel B Nelson; Qiang Wei; Wenhua Huang; Zhou Wang
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

7.  Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules.

Authors:  Khalid Z Masoodi; Yadong Xu; Javid A Dar; Kurtis Eisermann; Laura E Pascal; Erica Parrinello; Junkui Ai; Paul A Johnston; Joel B Nelson; Peter Wipf; Zhou Wang
Journal:  Mol Cancer Ther       Date:  2017-06-27       Impact factor: 6.261

8.  Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.

Authors:  Khalid Z Masoodi; Kurtis Eisermann; Zhenyu Yang; Javid A Dar; Laura E Pascal; Minh Nguyen; Katherine O'Malley; Erica Parrinello; Firuz G Feturi; Alex N Kenefake; Joel B Nelson; Paul A Johnston; Peter Wipf; Zhou Wang
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

Review 9.  Posttranslational modification of the androgen receptor in prostate cancer.

Authors:  Travis van der Steen; Donald J Tindall; Haojie Huang
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

10.  DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.

Authors:  Y Jing; M M Nguyen; D Wang; L E Pascal; W Guo; Y Xu; J Ai; F-M Deng; K Z Masoodi; X Yu; J Zhang; J B Nelson; S Xia; Z Wang
Journal:  Oncogene       Date:  2017-10-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.